Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions
- PMID: 22674947
- PMCID: PMC3229334
- DOI: 10.1136/bcr.09.2011.4756
Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions
Abstract
A 45-year-old man with bipolar disease type I and post-traumatic frontal lobe lesions following a previous psychotic episode was hospitalised after having stopped taking aripiprazole (15 mg/day) and lithium (126 mg twice/daily). He presented with hypomania, psychosis, verbal unresponsiveness and disorientation. He engaged in compulsive onanism in public which resulted in the restriction of his freedom, suggesting impulse control disorder (ICD). Electroencephalogram showed no epileptiform activity. Brain CT-scan showed post-traumatic bifrontal and left occipital lesions. Viral and bacterial serologies were normal. Lithium was initially reinstated (same dose), but it was aripiprazole reinstatement at a lower dose (10 mg) that made his condition rapidly improve within 24-36 h. Aripiprazole is a partial dopamine D2-receptor antagonist that blocks dopamine at higher dopamine concentrations and augments/releases prefrontal cortex dopamine at lower concentrations. The rapid recovery suggests stabilisation of dopamine levels in the frontal lobes and that ICD may be modified by aripiprazole treatment.
Conflict of interest statement
Figures
Similar articles
-
Pathological gambling and the treatment of psychosis with aripiprazole: case reports.Br J Psychiatry. 2011 Aug;199(2):158-9. doi: 10.1192/bjp.bp.110.084996. Br J Psychiatry. 2011. PMID: 21804151
-
Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation.J Clin Psychiatry. 2006 Aug;67(8):1311. doi: 10.4088/jcp.v67n0821f. J Clin Psychiatry. 2006. PMID: 16965218 No abstract available.
-
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.Drugs. 2004;64(15):1715-36. doi: 10.2165/00003495-200464150-00010. Drugs. 2004. PMID: 15257633 Review.
-
Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder.Acta Neuropsychiatr. 2014 Feb;26(1):61-4. doi: 10.1017/neu.2013.50. Acta Neuropsychiatr. 2014. PMID: 25142102
-
Aripiprazole: in acute mania associated with bipolar I disorder.CNS Drugs. 2004;18(6):367-76; discussion 377-8. doi: 10.2165/00023210-200418060-00007. CNS Drugs. 2004. PMID: 15089107 Review.
References
-
- DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649–66 - PubMed
-
- Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123–36 - PubMed
-
- Keck PE, Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626–37 - PubMed
-
- Stoffels C, Munari C, Bonis A, et al. Genital and sexual manifestations occurring in the course of partial seizures in man. Rev Electroencephalogr Neurophysiol Clin 1980;10:386–92 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical